SIM - Worlds First Instrumented Incontinence Assessment Solution

Transcription

1 SIM - Worlds First Instrumented Incontinence Assessment Solution An Investment in the Care of Ageing People Presented by: Philippa Lewis CEO June 2014 PAGE 1 Simavita Limited Commercial in Confidence

2 Disclaimer This document has been prepared by Simavita Limited (Simavita) and comprises written materials/slides for a presentation concerning Simavita. This presentation has been prepared by Simavita for professional investors. The information contained in this presentation is for information purposes only and does not constitute an offer or solicitation to sell or to issue, or arrange to sell or issue, securities or other financial products. Any such offer or solicitation will be made only by means of a confidential information memorandum and in accordance with applicable securities and other laws. The information contained in this presentation is not investment or financial product advice, is not intended to be used as the basis for making an investment decision, and no specific recommendations are intended. The presentation has been prepared without taking into account the investment objectives, financial situation or particular need of any particular person. No representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in the presentation. To the maximum extent permitted by law, none of Simavita, its related companies and their respective directors, employees or advisers, nor any other person accepts any liability, including, without limitation, any liability arising out of fault. Certain statements in this presentation are forward looking statements. These forward looking statements speak only as at the date of this presentation. These statements, by their nature, are subject to a number of known and unknown risks and uncertainties that could cause the actual results, performances and achievements to differ materially from any expected future results, performance or achievements expressed or implied by such forward looking statements. No representation, warranty or assurance (express or implied) is given or made by Simavita that the forward looking statements contained in this presentation are accurate, complete, reliable, or adequate or that they will be achieved or prove to be correct. Except for any statutory liability which cannot be excluded, each of Simavita, its related companies and their respective directors, employees and advisers expressly disclaim any responsibility for the accuracy or completeness of the forward looking statements and exclude all liability whatsoever (including negligence) for any direct or indirect loss or damage which may be suffered by any person as a consequence of any information in this presentation or any error or omission therefrom. PAGE 2 Simavita Limited Commercial in Confidence

3 Simavita Investment Case Why is this such an exciting investment? Massive market, global mega trend Incontinence is ubiquitous in the aging population everywhere Commercialized a real product that works! Makes aged care smarter, better, and reduces costs Global first mover Strong patent protection Automating a compulsory manual process PAGE 3 Simavita Limited Commercial in Confidence

4 The Manual Assessment Regulated, Compulsory and Ubiquitous 72 hours Check and change every 1-2 hours Expensive Labour intensive Inaccurate Not evidence based Cannot be validated Creates a very poor care plan PAGE 4 Simavita Limited Commercial in Confidence

5 Incontinence by Numbers Simavita s Global Market 240 Million people in the western world are incontinent 15+ Million incontinence assessments /year $6 Billion assessment labor costs /year (nursing homes only) $9 Billion continence products sold /year #2 nursing home cost (after labor) 25%+ of labor attributed to incontinence management in aged care facilities 70%+ of residents in aged care are incontinent PAGE 5 Simavita Limited Commercial in Confidence

6 SIM World s first Integrated and Instrumented Incontinence Assessment PAGE 6 Simavita Limited Commercial in Confidence PAGE 6 Simavita Limited Commercial in Confidence

7 SIM 72 Hour Bladder Chart SIM TM provides Big Data PAGE 7 Simavita Limited Commercial in Confidence PAGE 7 Simavita Limited Commercial in Confidence

8 SIM Summary Observations Clinical Guidelines The key to cost and outcomes: When to toilet? When to change? What product to prescribe? PAGE 8 Simavita Limited Commercial in Confidence PAGE 8 Simavita Limited Commercial in Confidence

9 Published Peer Reviewed Research Statistically Significant (Journal of Clinical Nursing) Effective continence management can significantly improve the patients health outcome through early detection and management of urinary incontinence reducing a range of associated problems including: Reduce risk of urinary tract infections, Reduce risk of skin breakdown, Reduce risk of falls and adverse or aggressive behaviours. Positive continence management leads to patient s regaining independence, improved socialisation and overcomes depression associated with incontinence. Study outcome; Using SIM, caregivers were able to greatly improve incontinence management in a short-time frame - within 2 weeks. Reduced volume of urine voided into continence aids Increased number of successful toileting events Increased adherence to urinary continence care plans by staff PAGE 9 Simavita Limited Commercial in Confidence

10 The SIM Customer Significant Financial Benefits And Improved Quality of Care Supports the Key Revenue Drivers for Residential Aged Care Facilities Reputation/Occupancy Government Funding Delivers proven Cost savings Labor Consumables Time management Waste Generates BIG DATA Care Plans, Toileting, Staff Rostering, Product Prescription, Undiagnosed Related Conditions PAGE 10 Simavita Limited Commercial in Confidence

11 Patient Benefits Person centered evidence based Less distress and physical intervention during assessment Right product selection (pads) Increased socialisation Less challenging and aggressive behaviours Less toileting Improved skin integrity less ulcers Less falls Co-related conditions are identified and treated more quickly PAGE 11 Simavita Limited Commercial in Confidence

12 Strong IP Proprietary Technology: Sensors Algorithms Incontinence management software and methods Proprietary incontinence patient databank Easy-to-use interface to complex data Broad and deep Patent Portfolio: 11 patent families; numerous independent claims 3 granted patents; 2 Australia, 1 US and Japan - global coverage pending Global exclusive license to two CSIRO patent portfolios High value patenting fields: Incontinence management methods; other clinical applications; algorithms and software; manufacturing methods PAGE 12 Simavita Limited Commercial in Confidence

13 US Market The Costs of Continence Management Long Term Care facilities total 2,700,000 beds Urinary Incontinence costs $7,300 per bed per annum in labor alone Or $19.9 billion based on 2,700,000 institutional beds SIM reduces labor and other costs and improves occupancy SIM results in a net savings of around $1,580 per bed per annum 1. Labour Costs associated with Urinary Incontinence in long term care facilities (Shih YC et all 2003) 2. Costs of Urinary Incontinence and overactive bladder in the United States: a comparative study (Hu TW et all 2004) 3. BSL Data Series - Consumer Price Index - Medical Care ( ) PAGE 13 Simavita Limited Commercial in Confidence

14 Medline Exclusive US Distribution Partner Medline Industries Inc., head office, Chicago, Illinois Revenue USD 7b+ 2012, #79 private company Forbes 1100 sales reps and 37 distribution centers Largest privately held manufacturer and distributor of healthcare products in the US Leading provider of adult incontinence products to the US healthcare market High quality training through Medline University Manufactures incontinence products in Atlanta, Georgia PAGE 14 Simavita Limited Commercial in Confidence

15 US Market Simavita Revenue Model Per Site Revenue model for SIM in US Long Term Care One off Software Sale Annual Software Licence Sale of Hardware Recurring Annual Sensor Sales PAGE 15 Simavita Limited Commercial in Confidence PAGE 15 Simavita Limited Commercial in Confidence

16 RACF Scheduled Roll Out (Residential Aged Care Facilities) PAGE 16 Simavita Limited Commercial in Confidence PAGE 16 Simavita Limited Commercial in Confidence

17 SIM Assessment Addressable Market Target Market Total Residential Aged Care Beds United States 2,700,000 Australia 180,000 Canada 250,000 Europe 3,300,000 Japan 740,000 Total 7,170,000 PAGE 17 Simavita Limited Commercial in Confidence

18 Platform Technology The Bigger Story Long Term Care assessment is the first application Additional potential applications in; i. Community Care ii. Data Management iii. Everyday monitoring PAGE 18 Simavita Limited Commercial in Confidence

19 Update Australia USA Canada Europe Canada USA Europe Australia PAGE 19 Simavita Limited Commercial in Confidence PAGE 19 Simavita Limited Commercial in Confidence

20 Simavita Limited Corporate Snapshot Cash on hand (31 May 2014) $4.6m Monthly burn $600K Growing revenue Shares Listed on TSXV, Canada CDIs Listed on ASX, Australia Australia, US 6 th December 2013, Code SV 20 th February 2014, Code SVA Number of Shares on Issue 58,766,653 Share Price (@ 17 June) Market Capitalisation Options/Warrants on Issue AUD$0.51 AUD$30m approx. 9,186,207 Strike price AUD$ , Expiry 3-5 years PAGE 20 Simavita Limited Commercial in Confidence

21 Contacts Australia Philippa Lewis CEO Simavita Limited Mobile plewis@simavita.com Website Jane Lowe Investor Relations Account Director Buchan Consulting Mobile jlowe@buchanwe.com.au Website PAGE 21 Simavita Limited Commercial in Confidence

22 Thank you PAGE 22 Simavita Limited Commercial in Confidence